Biotech Ligand Gets Sweeter Deal From Partner Viking

By | April 10, 2015

Scalper1 News

Shares of early-stage development biotech Ligand Pharmaceuticals (LGND) rose 3.3% to 83.20 after it disclosed that it would receive higher royalty rates on drugs licensed to partner Viking Therapeutics, which on Friday re-filed terms for an IPO. The compounds covered under the amended licensing agreement are meant to treat hip fractures, anemia and metabolic and lipid disorders. The agreement also amended terms of upfront payments to Ligand for Scalper1 News

Scalper1 News